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Abstract: Several monogenic defects have been reported 
to be associated with idiopathic short stature. Focusing 
on growth hormone receptor (GHR)-gene alterations, the 
heterozygosity of the same gene defect may be associ-
ated with a range of growth deficits. We found a heterozy-
gous mutation (V144I) within exon 6 of the GHR gene in a 
patient with a low level of insulin-like growth factor I (IGF-
I), normal level of GH, and severe short stature. Despite 
the lack of statistical difference, an overall tendency for 
reduced wt-GH-induction of GHR activation and Jak/Stat 
signalling in cells transiently expressing GHR-V144I alone 
or co-expressing wt-GHR compared to cells expressing 
only wt-GHR was found when GH doses were increased. 
Our results suggest that, although GHR sequence variants 
are responsible for some functional alterations commonly 
observed in children with idiopathic short stature, these 
changes may not explain all the height deficits observed 
in these subjects.
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Introduction
Idiopathic short stature (ISS) is defined as a condition, 
in which height is more than two standard deviations 
(SD) below the corresponding mean height for a given 
age, sex and population group, without evidence of 
any systemic, endocrine, nutritional or chromosomal 
abnormalities. In other words, ISS designates an unex-
plained condition even after a thorough growth evalua-
tion (1). Specifically, children with ISS have normal birth 
weight and normal growth hormone (GH) secretion (1). 
However, an increasing amount of disorders should be 
excluded in the process of ISS diagnosis (1, 2). While 
focusing on ISS and searching for possible causes of ISS, 
several monogenic causes of short stature have been 
reported to be “associated” with ISS. Importantly, these 
various disorders need to be excluded before the diagno-
sis of ISS can be made. These mutations include defects 
in GH-1, growth hormone-releasing hormone receptor 
(GHRHR), GH receptor gene (GHR), as well as various 
other genes, such as signal transducer (STAT5B), IGF-I 
and IGF-acid labile subunit (ALS), and so on (3). With 
an increasing number of reports on these gene defects, 
it has become evident that there is no strict geno/phe-
notype correlation; furthermore, phenotypes are highly 
variable. Focusing on GHR gene alterations, the clinical 
features of homozygous gene defects (mutations or dele-
tions) can vary substantially depending on the location 
of the genetic alteration. Furthermore, another cause of 
clinical variability may be the heterozygosity of the same 
gene defect, which may be associated with only a mild 
negative effect on growth or in some cases pronounced 
growth failure (4). In addition, it is possible that primary 
IGF-I deficiency may be associated with cumulative 
digenic or oligogenic defects, as supported by the results 
from genome-wide association studies, which found that 
height is determined by more than 180 genes (5). There-
fore, in order to diagnose short stature correctly, a genetic 
analysis, in addition to the functional proof of any gene 
defect found, is essential in the diagnostic workup of a 
patient with short stature (4).
Clinical report
The proband was a 2-year-old female, the second child of 
healthy, non-consanguineous Senegalese parents. The 
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family history was unremarkable. She was born at term (38 
weeks and 5 days) by cesarean section, length was 48 cm 
(25th percentile), weight of 2.40 kg (3rd–10th percentile), 
and a head circumference of 33 cm (25th percentile) (6). 
Maternal and paternal heights were 163 cm (0.13 SDS) and 
183  cm (1.25 SDS), respectively, and her parental target 
height was 166.5 cm (0.72 SDS) (7), as shown in Figure 1. 
The target height was calculated using the following 
formula: [(maternal height cm+paternal height cm)/2]+6.5 
if male or [(maternal height cm+paternal height cm)/2]–
6.5 if female.
At birth, she was treated with erythropoietin for 2 days 
(dosage not recorded) for severe anemia (Hb: 10.5 g). At 
the age of 7.5 months, she was admitted to the hospital 
for reduced food intake with stunted growth and weight 
loss, exhibiting height of 65 cm (–2.06 SDS) and a BMI of 
13.54 (–2.09 SDS) (7). She presented with proportionate 
short stature and normal psychomotor development, an 
umbilical hernia, and some craniofacial features such as 
frontal bossing and saddle nose. Chronic diseases, includ-
ing hypothyroidism, celiac and metabolic diseases, were 
excluded.
At the age of 1.1 year, her height was 69 cm (–3.09 SDS) 
and growth velocity was 8 cm/year (–3.32 SDS) (7). At the 
age of 2 years, her height was 77 cm (–2.3 SDS) and her BMI 
was 14.34 (–1.29) (7) (Figure 2). An endocrine evaluation 
showed a very high GH basal value (47 ng/mL), which was 
unchanged after pharmacological stimulus (chloridrate 
arginine infusion) (8), and a very low level of basal IGF1 
( < 25 ng/mL).
The discrepancy between the very high GH basal 
values and the very low levels of IGF-I suggested GH insen-
sitivity as the cause of short stature. To verify insensitivity 
to GH, an IGF-I stimulation test was performed according 
the classical scheme of 0.1 IU/kg/die GH for 4 days. No 
IGF-I increase (from 50 to 56 ng/mL) was observed, thus 
confirming the diagnosis of GH insensitivity (9).
H: 163 cm
H: 163 cm H: 158 cm
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H: 183 cm
Figure 1 Patient’s pedigree. The known heights of the patient’s 
relatives are indicated.
Treatment with rIGF-I injections was proposed to 
improve growth, but it was rejected by the family because 
of side effects. At her last visit at the age of 2.4 years, her 
height was 80.7  cm (–2.3 SDS) and BMI was 13.82 (–1.57 
SDS) (6) (Figure 3).
Materials and methods
Molecular studies
Genomic DNA was isolated from the peripheral blood mononuclear 
cells of the patient and her immediate family (father, mother, and 
brother). Mutation analysis was carried out by direct sequencing of 
all exons and the flanking region of the GHR gene, using the sequence 
kit Dye Terminator (Applied Biosystems, Monza, Italy) with on ABI 
PRISM 310 automatic sequencer (Applied Biosystems, Monza, Italy).
Luciferase reporter gene assay of Stat5 
activation
Hek293 TLA cells were transiently transfected with pcDNA 1 wt-GHR 
and/or pcDNA GHR-V144I plasmids using the calcium-phosphate 
transfection agent (Invitrogen, Life Technologies Europe B.V., Zug, 
Switzerland) according to the manufacturer’s instructions. After 
48 h of incubation, cells were seeded in 12-well plates at a density 
of 160,000 cells/well and the Stat5 activation assay was performed 
as previously described (10, 11). Briefly, cells were transfected 
with a Stat5-responsive luciferase reporter gene construct (12, 13) 
and treated with increasing amounts of wt-GH for 6 h. Luciferase 
expression was then measured by the dual luciferase reporter assay 
( Promega, Dubendorf, Switzerland) on a luminometer (Mediators 
PhL, Aureon Biosystems, Vienna, Austria).
Results
Genetic analysis
Genetic analysis revealed a heterozygous mutation at 
nucleotide 484 (first base position of the codon 144) 
within exon 6 of the GHR gene of the proband, resulting 
in a predicted change from valine to isoleucine (V144I). 
The patient’s brother and father were heterozygous and 
homozygous, respectively, for the mutation.
In vitro study
In order to test and compare wt-GH-induced activation 
of the Jak/Stat pathway of wt-GHR and/or the GHR-V144I 
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mutant, the Stat5 activation assay was performed using 
Hek293 TLA cells transiently expressing wt-GHR, GHR-
V144I mutant, or equal amounts of both (GHR wt/wt, GHR 
V144I/V144I, GHR wt/V144I). With increasing rhGH expo-
sure, we observed an overall tendency of reduced Jak/
Stat signalling in cells expressing GHR wt/V144I and GHR 
V144I/V144I compared with GHR wt/wt when stimulated 
with 100 and 400 ng/mL of wt-GH. However, the results 
were not statistically significant (Figure 4).
Discussion
It is a considerable challenge for clinicians to distinguish 
ISS from partial GH deficiency. There is no gold standard 
Figure 2 Patient’s growth chart. All height measurements taken from 7.5 months of age to 2.4 years of age.
Figure 3 Patient at 2.4 years of age exhibiting a frontal bossing, 
prominent forehead, hypoplasic nasal bridge, and scleras blue.
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pharmacological test that can establish normal GH secre-
tion due to arbitrary cut-off levels and low accuracy (14). 
Thus, children with test results may be false-positive diag-
nosed as partial GHD, and vice versa false-negative may 
be labeled as ISS (15).
It has been suggested that GHR-gene alterations may 
account for up to 5% of all ISS patients, and that these 
mutations should be taken into consideration when other 
causes of short stature have been ruled out (16). Thus, the 
correlation between heterozygous mutations in the GHR 
gene and ISS has been explored in various studies with 
conflicting results.
Several abnormal forms of the GHR have been identi-
fied, which result in abnormal GH binding, defective recep-
tor dimerization, and defective signal transduction (17). 
However, it is uncertain whether heterozygous mutations 
in GHR play a major role in determining growth (18, 19).
In our case, we found a transition from G to A at posi-
tion 1 of codon 144 of the GHR gene, resulting in the non 
synonymous amino acid (aa) change from valine to iso-
leucine. The same change has been reported by Sanchez 
et al. (19). Another nucleotide change in the same amino 
acid (second base pair of codon 144 as opposed to the 
first in our patient) has also been found in a compound 
heterozygous patient with Laron syndrome in a report by 
Amselem et al. (20).
Our patient presented with low levels of IGF-I, normal 
values of GH and clinically severe short stature, which did 
not correlate with her mid-parental height. These param-
eters are often associated with the V144I heterozygous 
mutation in the GHR gene. However, her father who was 
homozygous for the same mutation, and her brother, who 
carried the mutation in a heterozygous state, were both 
of normal height, thus underlining the absence of a strict 
geno-/phenotype correlation. In addition, our finding 
that family members of normal stature carrying the same 
sequence change as the patient challenges the concept 
that GHR-V144 plays a major role in determining height 
velocity, growth and eventually final height, although 
some impacts on GHR signaling cannot be ruled out.
In previous studies, Sanchez et al. (19) and Amselem 
et al. (20) have found a correlation between this mutation 
and its function. In fact, Sanchez et al. reported that one 
patient presented with partial growth hormone insensitiv-
ity (GHI) and that family members with the same heterozy-
gous mutations are of short stature (19). Furthermore, a 
patient described by Amselem et al. (20) has been found 
to be compound heterozygous with an aa change at the 
same locus, but resulting in a valine to aspartic acid 
substitution that, in turn, causes GHIS. In contrast with 
our results, these studies suggest that the valine at posi-
tion 144 is likely to be important for proper GH-receptor 
function. However, in both cases, the significance of the 
V144I mutation has yet to be determined using functional 
studies.
A dominant negative effect of a heterozygous mutation 
can be expected in some cases, where the dimerization of 
the mutant with the wild-type variant interferes in terms 
of formation and, thereafter, the activity of the hormone-
receptor complex. Importantly, this fact must be analyzed 
by functional studies, but bearing in mind that in vitro 
results are not always predictive of a clinical effect (3).
Nevertheless, we tested the Jak/Stat signaling capac-
ity of wt-GHR and/or GHR-V144I mutant and found an 
overall tendency for a reduced Jak/Stat signalling in cells 
expressing GHR wt/V144I and GHR V144I/V144I com-
pared to GHR wt/wt after stimulation with wt-GH, but the 
data did not reach statistical significance (Figure 4).
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Figure 4 Jak2/Stat5 signaling capacity of GHR wt and/or GHR V144I evoked by wt-GH. The normalized firefly/renilla luciferase activity of 
wt-GH-stimulated cells was divided by the normalized activity of unstimulated samples (SM), yielding the fold induction. Furthermore, 
activation of Jak/Stat signalling of GHR wt evoked by 400 ng/mL wt-GH [GHR wt/wt (max)] was set at 100% and other measurements were 
compared against this. The results are given as the means ± SD of three separate experiments performed in duplicate.
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Finally, although sequence variants within the GHR 
gene are very common in children with ISS and a high 
frequency of sequence changes in the GHR gene in short 
children with characteristics of GHI has been reported 
(18), our results suggest that these changes may not 
play a major role in determining growth and eventually 
final height (19–21). Along this line, the presence of the 
identical sequence change in family members of normal 
stature suggests that these sequence variants do not 
influence the function of GHR at all. Furthermore, it is 
possible that other factors, such as environmental, epi-
genetics as well as other more important genes and their 
interaction, may explain the insensitivity to GH in chil-
dren with GHI (3–5).
For instance, Lango et al. (22) have reported that hun-
dreds of genetic variants, in at least 180 loci, influence 
adult height, indicating that height and growth are highly 
heritable and classic polygenic traits. These loci are non-
randomly clustered within biologically relevant pathways 
and are enriched for genes involved in growth-related pro-
cesses, which underlie syndromes of abnormal skeletal 
growth, and are directly relevant to growth-modulating 
therapies.
In conclusion, we present a patient suffering from a 
heterozygous GHR gene mutation, previously described as 
causing short stature and GHI. Functional analysis data, 
however, do not fully support the concept that this V144I 
GHR variant is the unique cause for short stature in this 
girl. Importantly, as growth is a classic polygenic trait 
involving nearly 200 genes along with environmental and 
epigenetic factors, there is a need to broaden the analyses 
when studying possible causes for short stature.
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